Cardiff Oncology (CRDF) Operating Income (2016 - 2025)
Historic Operating Income for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to -$12.0 million.
- Cardiff Oncology's Operating Income rose 497.58% to -$12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.7 million, marking a year-over-year decrease of 1571.61%. This contributed to the annual value of -$48.7 million for FY2024, which is 713.25% down from last year.
- As of Q3 2025, Cardiff Oncology's Operating Income stood at -$12.0 million, which was up 497.58% from -$14.8 million recorded in Q2 2025.
- In the past 5 years, Cardiff Oncology's Operating Income ranged from a high of -$5.4 million in Q1 2021 and a low of -$14.8 million during Q2 2025
- For the 5-year period, Cardiff Oncology's Operating Income averaged around -$10.7 million, with its median value being -$10.9 million (2024).
- As far as peak fluctuations go, Cardiff Oncology's Operating Income tumbled by 10349.14% in 2022, and later surged by 928.48% in 2024.
- Over the past 5 years, Cardiff Oncology's Operating Income (Quarter) stood at -$9.5 million in 2021, then increased by 1.41% to -$9.4 million in 2022, then dropped by 10.01% to -$10.3 million in 2023, then decreased by 21.68% to -$12.6 million in 2024, then rose by 4.76% to -$12.0 million in 2025.
- Its Operating Income was -$12.0 million in Q3 2025, compared to -$14.8 million in Q2 2025 and -$14.4 million in Q1 2025.